Skip to main content
FDA grants fast-track designation to Karyopharm's multiple myeloma drug

Selinexor, Karyopharm Therapeutics' treatment for patients with multiple myeloma who have undergone at least three previous lines of therapy, was granted fast-track designation by the FDA. Top-line data from a study evaluating the drug is expected to be released by the end of the month.

Full Story: